The March edition of French publication Biotech-Finances featured a two-page Q&A with CEO Henry Skinner, in which he emphasized the need for policymakers across the G7 to incentivize antimicrobial R&D and take steps to ensure the marketplace for these drugs is more predictable. He added that investors, academia, government institutions, biotech companies, and larger pharma companies all have a role to play in creating a sustainable R&D ecosystem.
A version of the interview in French can be found here.
